News for Amphastar Pharmaceuticals, Inc. (AMPH)

With big American pharmaceutical corporations always searching for medications in China, the US pharmaceutical industry is going through a unique trend never seen before.

Recognized for contributions to address shortage of epinephrine injection, 0.1 mg/mL syringes RANCHO CUCAMONGA, CA / ACCESS Newswire / March 28, 2025 / Amphasta

Shares of Amphastar Pharmaceuticals Inc (AMPH) surged 1.36% in mid-day trading on Mar 22. The stock reached an intraday high of $28.44, before settling at $28

Shares of Amphastar Pharmaceuticals Inc (AMPH) surged 0.46% in mid-day trading on Mar 19. The stock reached an intraday high of $27.86, before settling at $27

March 17, 2025 (Maple Hill Syndicate) ”“- The Nasdaq Stock Market led the way up in the great rally of the past two years. Now it's leading the way down.Nasdaq

Amphastar Pharmaceuticals Inc (AMPH) has announced that its CFO, Bill Peters, and EVP of Regulatory Affairs and Clinical Operations, Tony Marrs, will present at

Shares of Amphastar Pharmaceuticals Inc (AMPH) fell 3.24% in mid-day trading on Mar 3. The stock reached an intraday low of $27.29, before recovering slightly

Shares of Amphastar Pharmaceuticals Inc (AMPH) fell 9.30% in mid-day trading on Feb 28. The stock reached an intraday low of $27.82, before recovering slightl

Release Date: February 27, 2025For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Amphastar Ph

Refinitiv StreetEvents Event TranscriptE D I T E D V E R S I O NAMPH.OQ - Amphastar Pharmaceuticals IncQ4 2024 Amphastar Pharmaceuticals Inc Earnings CallFeb

Amphastar Pharmaceuticals Inc. (NASDAQ:AMPH) Q4 2024 Earnings Conference Call February 27, 2025 5:00 PM ETCompany ParticipantsDan Dischner - Senior Vice...

Reports Net Revenues of $186.5 Million for the Three Months Ended December 31, 2024 RANCHO CUCAMONGA, CA / ACCESS Newswire / February 27, 2025 / Amphastar Pharm

Amphastar (AMPH) delivered earnings and revenue surprises of -4.17% and 1.08%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Quarterly Revenue: $186.5 million, slightly below the estimated $188.81 million.Quarterly GAAP EPS: $0.74, missing the estimated EPS of $0.93.Quarterly Adjuste

Amphastar Pharmaceuticals (AMPH) Q4 earnings report is set for Feb 27 post-market. Analysts predict $0.94 EPS (+6.8% Y/Y) & $188.78M revenue (+6.0% Y/Y).

Summary Amphastar Pharmaceuticals Inc (AMPH), a biopharmaceutical company specializing in injectable, inhalation, and intranasal products, announced that it wil

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a...

Amphastar Pharmaceuticals has a growth model based on organic growth and acquisitions, though competition and patent expirations pose risks. Read more here.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...